Ultragenyx Pharmaceutical (NASDAQ:RARE) PT Lowered to $60.00
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) had its price target reduced by Evercore ISI to $60.00 in a report issued on Tuesday, Stock Target Advisor reports. Evercore ISI's target price would indicate a potential upside of 15.03% from the stock's current price.
Several other brokerages have also recently commented on RARE. The Goldman Sachs Group decreased their target price on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a 'neutral' rating on the stock in a report on Tuesday, May 24th.